{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T12:30:36Z","timestamp":1679574636054},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,7,23]],"date-time":"2018-07-23T00:00:00Z","timestamp":1532304000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s00108-018-0470-x","type":"journal-article","created":{"date-parts":[[2018,7,23]],"date-time":"2018-07-23T06:13:55Z","timestamp":1532326435000},"page":"1208-1213","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Was am Herzen nagt und auf die Nerven geht"],"prefix":"10.1007","volume":"59","author":[{"given":"Arnt V.","family":"Kristen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,23]]},"reference":[{"issue":"6","key":"470_CR1","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1056\/NEJMra023144","volume":"349","author":"G Merlini","year":"2003","unstructured":"Merlini G, Bellotti V (2003) Molecular mechanisms of amyloidosis. N\u00a0Engl J Med 349(6):583\u2013596","journal-title":"N Engl J Med"},{"issue":"3","key":"470_CR2","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s00292-011-1558-4","volume":"33","author":"AV Kristen","year":"2012","unstructured":"Kristen AV, R\u00f6cken C (2012) Amyloidose des Herzens. Pathologe 33(3):236\u2013244","journal-title":"Pathologe"},{"key":"470_CR3","first-page":"408","volume-title":"A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 75(3)","author":"C Andrade","year":"1952","unstructured":"Andrade C (1952) A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 75(3), S\u00a0408\u2013427"},{"issue":"6","key":"470_CR4","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1001\/archneur.1968.00470360015001","volume":"18","author":"S Araki","year":"1968","unstructured":"Araki S, Mawatari S, Ohta M, Nakajima A, Kuroiwa Y (1968) Polyneuritic amyloidosis in a\u00a0Japanese family. Arch Neurol 18(6):593\u2013602","journal-title":"Arch Neurol"},{"key":"470_CR5","first-page":"1","volume":"590","author":"R Andersson","year":"1976","unstructured":"Andersson R (1976) Familial amyloidosis with polyneuropathy. A clinical study based on patients living in northern Sweden. Acta Med Scand Suppl 590:1\u201364","journal-title":"Acta Med Scand Suppl"},{"issue":"9","key":"470_CR6","doi-asserted-by":"publisher","first-page":"4499","DOI":"10.1073\/pnas.75.9.4499","volume":"75","author":"PP Costa","year":"1978","unstructured":"Costa PP, Figueira AS, Bravo FR (1978) Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy. Proc Natl Acad Sci U S\u00a0A 75(9):4499\u20134503","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"470_CR7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/13506120600722449","volume":"13","author":"Y Sekijima","year":"2006","unstructured":"Sekijima Y, Dendle MT, Wiseman RL, White JT, D\u2019Haeze W, Kelly JW (2006) R104H may suppress transthyretin amyloidogenesis by thermodynamic stabilization, but not by the kinetic mechanism characterizing T119 interallelic trans-suppression. Amyloid 13(2):57\u201366","journal-title":"Amyloid"},{"issue":"21","key":"470_CR8","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","volume":"66","author":"MA Gertz","year":"2015","unstructured":"Gertz MA, Benson MD, Dyck PJ, Grogan M, Coelho T, Cruz M, Berk JL, Plante-Bordeneuve V, Schmidt HHJ, Merlini G (2015) Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis. J\u00a0Am Coll Cardiol 66(21):2451\u20132466","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"470_CR9","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/eurheartj\/ehs123","volume":"34","author":"C Rapezzi","year":"2013","unstructured":"Rapezzi C, Quarta CC, Obici L, Perfetto F, Longhi S, Salvi F, Biagini E, Lorenzini M, Grigioni F, Leone O, Cappelli F, Palladini G, Rimessi P, Ferlini A, Arpesella G, Pinna AD, Merlini G, Perlini S (2013) Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart\u00a0J 34(7):520\u2013528","journal-title":"Eur Heart J"},{"key":"470_CR10","first-page":"88","volume":"1980","author":"P Coutinho","year":"1980","unstructured":"Coutinho P, da Silva AM, Lima JL, Glenner GG, e\u00a0Costa PP, de\u00a0Freitas AF et\u00a0al (1980) Forty years of experience with type 1 amyloid neuropathy: review of 483 cases. Amyloid and Amyloidosis.  Excerpta Medica 1980:88\u201398","journal-title":"Excerpta Medica"},{"issue":"7","key":"470_CR11","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1093\/eurheartj\/ehs123","volume":"34","author":"C Rapezzi","year":"2013","unstructured":"Rapezzi C, Quarta CC, Obici L, Perfetto F, Longhi S, Salvi F, Biagini E, Lorenzini M, Grigioni F, Leone O, Cappelli F, Palladini G, Rimessi P, Ferlini A, Arpesella G, Pinna AD, Merlini G, Perlini S (2013) Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart\u00a0J 34(7):483\u2013485","journal-title":"Eur Heart J"},{"key":"470_CR12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nrcardio.2014.165","volume":"12","author":"MA Gertz","year":"2015","unstructured":"Gertz MA, Dispenzieri A, Sher T (2015) Pathophysiology and treatment of cardiac amyloidosis. Nature Reviews Cardiology 12: 91\u2013102","journal-title":"Nature Reviews Cardiology"},{"issue":"3","key":"470_CR13","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/j.1399-0004.1991.tb03085.x","volume":"40","author":"G Holmgren","year":"1991","unstructured":"Holmgren G, Steen L, Ekstedt J, Grot CG, Ericzon BG, Eriksson S, Andersen O, Karlberg I, Nord\u00e9n G, Nakazato M et al (1991) Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet 40(3):242\u2013246","journal-title":"Clin Genet"},{"issue":"2","key":"470_CR14","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1177\/1756285612470192","volume":"6","author":"D Adams","year":"2013","unstructured":"Adams D (2013) Recent advances in the treatment of familial amyloid polyneuropathy. Ther Adv Neurol Disord 6(2):129\u2013139","journal-title":"Ther Adv Neurol Disord"},{"issue":"9","key":"470_CR15","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","volume":"99","author":"BG Ericzon","year":"2015","unstructured":"Ericzon BG, Wilczek HE, Larsson M, Wijayatunga P, Stangou A, Pena JR, Furtado E, Barroso E, Daniel J, Samuel D, Adam R, Karam V, Poterucha J, Lewis D, Ferraz-Neto BH, Cruz MW, Munar-Ques M, Fabregat J, Ikeda S, Ando Y, Heaton N, Otto G, Suhr O (2015) Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative? Transplantation 99(9):1847\u20131854","journal-title":"Transplantation"},{"issue":"7","key":"470_CR16","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/tri.12110","volume":"26","author":"FJ Bolte","year":"2013","unstructured":"Bolte FJ, Schmidt HH, Becker T, Braun F, Pascher A, Klempnauer J, Schmidt J, Nadalin S, Otto G, Barreiros AP (2013) Evaluation of domino liver transplantations in Germany. Transpl Int 26(7):715\u2013723","journal-title":"Transpl Int"},{"issue":"7618","key":"470_CR17","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussi\u00e8re T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O\u2019Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J (2016) C Hock RM Nitsch, A Sandrock. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature 537(7618):50\u201356","journal-title":"Nature"},{"issue":"10","key":"470_CR18","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s00392-012-0463-z","volume":"101","author":"AV Kristen","year":"2012","unstructured":"Kristen AV, Lehrke S, Buss S, Mereles D, Steen H, Ehlermann P, Hardt S, Giannitsis E, Schreiner R, Haberkorn U, Schnabel PA, Linke RP, R\u00f6cken C, Wanker EE, Dengler TJ, Altlan K, Katus HA (2012) Green tea halts progression of cardiac transthyretin amyloidosis: an observational report. Clin Res Cardiol 101(10):805\u2013813","journal-title":"Clin Res Cardiol"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-018-0470-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-018-0470-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-018-0470-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T19:34:17Z","timestamp":1563824057000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-018-0470-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,23]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["470"],"URL":"https:\/\/doi.org\/10.1007\/s00108-018-0470-x","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,23]]},"assertion":[{"value":"23 July 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.V.\u00a0Kristen gibt an, dass er f\u00fcr die Fa. Pfizer Inc und die Fa. Alnylam Pharmaceutical an der Durchf\u00fchrung von klinischen Studien und Vortr\u00e4gen, und an Advisory Boards beteiligt war, sowie Reisekostenunterst\u00fctzung erhielt. F\u00fcr die Fa.\u00a0Akcea Therapeutics f\u00fchrte er Vortr\u00e4ge durch und nahm an Advisory Boards teil, und erhielt Reisekostenunterst\u00fctzung.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine vom Autor durchgef\u00fchrten Studien an Menschen oder Tieren. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patienten zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}